Hiroshi Date
Duke University · 1,279 works · 21,306 citations · h-index 69
Top works
- The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers
- Pulmonary function, postoperative pain, and serum cytokine level after lobectomy: a comparison of VATS and conventional procedure
- Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer
- Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
- Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients
- Detection ofEGFRGene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- Thoracoscopic Operation for Secondary Pneumothorax Under Local and Epidural Anesthesia in High-Risk Patients
- PD-160 The relationship between epidermal growth factor receptor (EGFR) mutations and clinicopathologic features in non-small cell lung cancers
- Inhaled nitric oxide reduces human lung allograft dysfunction
- Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer
- Living-donor lobar lung transplantation for various lung diseases
- Prognosis of undetected intrapulmonary metastases in resected lung cancer
- Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib‐treated patients with lung adenocarcinoma
- Improved airway healing after lung transplantation
- Use of virtual assisted lung mapping (VAL-MAP), a bronchoscopic multispot dye-marking technique using virtual images, for precise navigation of thoracoscopic sublobar lung resection
- Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors
- Improved survival after living-donor lobar lung transplantation
- Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017)
- MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors